Thanks to one of our ICFDA Directors for obtaining the following for us:
The following message is a transcript of last night’s ABC News with
Peter Jennings: a message about the SSRIs. Tonight Peter Jennings will
discuss the “side-effects” of the SSRIs.
———————————————————————–
Peter Jennings ABC News: September 15, 1999
Peter Jennings: “Just when is the drug actually making a difference?
Antidepressants are very popular these days: sales are up 17% from just
last year. Millions and millions of prescriptions now are being
written to
battle depression and mood swings. Tonight, are these drugs really
doing
everything that people think they are? Here’s ABC’s Deborah Amos ”
Deborah Amos: “These depression fighting pills are 60 – 70% effective in
bringing relief according to the medical literature. But Thomas Moore,
who
studies drugs at George Washington University, says the numbers are
misleading”
Thomas Moore: “Millions of Americans believe that the benefits of these
drugs are much greater than they are”
Deborah Amos: “To investigate, Moore analyzed all drug company tests on
five major drugs submitted to the FDA prior to market approval: for
Paxil,
Zoloft, Effexor, Serzone and Prozac. The effectiveness of the drug was
measured against a placebo or sugar pill.”
Thomas Moore: “The effect of antidepressants drugs on depression is
only
very little different than the effect of a completely inactive placebo.”
Deborah Amos: “The highlight of Moore’s finding is the case of Prozac
with
more than $2 billion dollars in U.S. Sales. About 90% of Prozac’s
overall
effectiveness is about the same as patients taking nothing stronger
than a
sugar pill. But the label for antidepressant drugs, the prescribing
detail
for doctors, usually do not spell out the small overall differences
between
the drug and the placebos.”
Thomas Moore: “At the very least the FDA product labeling should
include a
more balanced picture of all the information they have received about
the
drug, – about all the clinical trials.”
Deborah Amos: “”The FDA says it does not put that kind of detail on the
label because it is not helpful in predicting individual outcomes. So
what
does it all mean for patients, when a placebo can have almost the same
benefits as a dug, and particularly, when a drug can have unpleasant
side-effects , —- that feeling – jumpy to <sum><sum><sum><sum><sum>
(a psychologist from the University of Conn., who has teamed up with
Thomas
Moore.)
?: “It suggests that the frontline of treatment for depression should
be
psychological rather than chemical.”
Deborah Ames: “The problem is that good therapy is expensive and not
always available. Pills are cheaper and more easily available. Deborah
Ames, ABC News, New York.”